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Pamala A. Jacobson,1 Jiayin Huang,1,2 Juan Wu,3 Miae Kim,1 Brent Logan,4 Amin Alousi,5
Michael Grimley,6 Javier Bolan˜os-Meade,7 Vincent Ho,8 John E. Levine,9 Daniel Weisdorf10There are limited data as to the effectiveness of mycophenolate mofetil (MMF) plus high-dose corticosteroids
for the treatment of acute graft-versus-host disease (aGVHD), and even less data regarding the pharmaco-
kinetic disposition and exposure–response relationship of MMF in individuals with GVHD. MMF pharmaco-
kinetics were studied in a multicenter Blood and Marrow Transplant Clinical Trials Network randomized
phase II trial evaluating the effectiveness of MMF as one of 4 agents added to corticosteroids as treatment
of aGVHD. Thirty-two of the patients randomized to receive MMF underwent pharmacokinetic sampling
in weeks 1 and 2 were studied. Mean age was 41 6 13.6 years. Twenty one (65.6%), 5 (15.6%), 6 (18.8%)
patients had a complete response (CR), partial response (PR) or lesser response by day 28, respectively.
Twenty-five (78.1%), 2 (6.3%), 5 (15.6%) patients had a CR, PR, or other response by day 56 to treatment,
respectively. Mycophenolic acid (MPA) pharmacokinetic measurements from weeks 1 and 2 did not correlate
with CR at either day 28 or day 56 (P . .07); however, if the mean of weeks 1 and 2 total MPA troughs was
.0.5 mg/mL or that of an unbound trough was .0.015 mg/mL, then a significantly greater proportion
achieved CR 1 PR at days 28 and 56. CR 1 PR at day 28 was observed in 19 of 19 patients (100%) with
a mean total trough .0.5 mg/mL, but in only 7 of 13 (54%) with a mean total trough #0.5 mg/mL (P 5
.002). Similarly, CR 1 PR at day 28 was seen in 15 of 15 patients (100%) with an unbound trough
concentration .0.015 mg/mL, but in only 11 of 17 (65%) with an unbound trough concentration #0.015
mg/mL (P 5 .02). There was no association between the pharmacokinetic measures and risk of infection
by day 90 or overall survival (OS) at day 180 postrandomization. About one-half of subjects did not achieve
the favorable MPA total and unbound trough concentrations. The current practice of MMF 1 gm twice daily
dosing provides low plasma concentrations in many patients. Higher doses may improve the efficacy of MMF
as aGVHD therapy.
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ing aGVHD, either in combination with steroid ther-
apy or as single agents [2-8]. Several newer agents,
including mycophenolate mofetil (MMF), have
emerged as potentially effective for aGVHD; however,
well-controlled trials defining the most effective agent
are lacking [9-15].
Recently, the Blood and Marrow Transplant Clin-
ical Trials Network (BMT CTN) conducted a multi-
center randomized phase 2 trial (BMT CTN 0302)
comparing corticosteroids combined with either eta-
nercept, MMF, denileukin diftitox, or pentostatin for
treating newly diagnosed aGVHD in 180 patients
who had undergone allogeneic HCT [16]. Compared
with the other arms, the MMF arm had a greater rate
of complete response (CR) at day 28 (60%; 95% con-
fidence interval [CI] 5 46%-74%) and day 56 (73%;
95% CI 5 60%-86%), and fewer treatment failures
at day 56 (9%; 95% CI 5 0.6%-17%), although no
formal statistical comparisons were done because of
the small numbers in the trial. These data suggest
that MMF may have significant activity against
aGVHD, and a follow-up phase III trial is planned
to confirm this. Given these findings, understanding
MMF exposure–response relationships and defining
the optimal dose for GVHD treatment is critical and
may further improve the efficacy of MMF.
MMFis a prodrugdesigned to enhance the bioavail-
ability of the active form, mycophenolic acid (MPA).
MMF is extensively hydrolyzed to MPA by esterases
located in the systemic circulation, gut wall, liver, and
tissues [17,18]. Glucuronidation of MPA occurs in the
kidney, liver, and intestine by uridine 5’-diphospho-
glucuronosyltransferases (UGTs) to the main inactive
metabolite, mycophenolic acid glucuronide (MPAG)
[19,20]. MPAG is then transported in the bile to the
gastrointestinal (GI) tract by multidrug-resistance
protein 2 or excreted into the urine by active tubular
secretion and eliminated [18]. MMF also may undergo
enterohepatic recirculation, in which biliary MPAG is
deglucuronidated to MPA by gut bacteria and then
reabsorbed into the systemic circulation [18,21,22].
MPA pharmacokinetic disposition and exposure–
response relationships in the setting of aGVHD treat-
ment are poorly understood. It is possible that more
intensive immunosuppression is required during
GVHD treatment, and that different MPA plasma tar-
gets may be required relative to GVHD prophylaxis.
In addition, MPA is highly dependent on metabolism
in the intestine and liver, and given that GVHD may
involve these sites, it is reasonable to speculate that
glucuronidation, enterohepatic recirculation, or bio-
availability might be altered. Although controversial,
data from organ transplantation and HCT suggest
that a minimal required plasma exposure of mycophe-
nolate is required for optimal immunosuppression in
the prophylactic setting [23-33]. Because of concernsthat exposure may be altered in the setting of aGVHD
[34], pharmacokinetic analyses were performed in
subjects on the MMF arm of BMT CTN 0302, and
the data are reported here. Our primary objective
was to evaluate the association between mycopheno-
late pharmacokinetics and aGVHD CR and partial
response (PR) at days 28 and 56 posttreatment.
Secondary objectives were to assess the relationships
between pharmacokinetics and the incidence of severe
infections and survival.METHODS
Study Design and Patients
This was a prespecified analysis in patients ran-
domized to the MMF arm of CTN 0302. Forty-five
patients aged $6 years with newly diagnosed
aGVHD requiring systemic treatment were treated
with MMF; pharmacokinetics were studied in 32 of
these patients. The patients received treatment with
MMF plus methylprednisolone 2 mg/kg/day i.v.
divided into 2-3 daily doses (or prednisone 2.4 mg/
kg/day orally) for aminimum of 7 days. A patient could
not have received previous systemic therapy for the
treatment of aGVHD, except for a maximum of 48
hours of high-dose steroid therapy (methylpredniso-
lone $1 mg/kg/day). All patients had undergone
related or unrelated allogeneic HCT. Patients with
an uncontrolled infection, absolute neutrophil count
(ANC) \500 cells/mL, or creatinine clearance #30
mL/min were ineligible. Patients also were ineligible
if they had received MMF for GVHD prophylaxis
within the 7 days before study enrollment. The study
was approved by each participating institution’s insti-
tutional review board (IRB) and the IRB of the BMT
CTN. All patients provided written informed consent.MMF Treatment
MMF (Cellcept; Roche, Nutley, NJ) was given at
a dose of 20 mg/kg twice daily orally or i.v. in patients
with a body surface area (BSA).1.5 m2 (maximum 1 g
twice daily) and 750 mg twice daily orally or i.v.
in those with a BSA \1.5 m2 at time of GVHD
diagnosis. The choice of oral or i.v. administration
was determined clinically at each site. Patients with
GI GVHD who were unable to tolerate more than
500mLof oral fluids/day received i.v.MMF for at least
the first 3 days of therapy. In patients with suspected
mycophenolate-related GI toxicity, the MMF dose
was reduced by 50%. MMF was discontinued in those
with persistent or severe GI symptoms. Likewise, the
MMF dose was reduced by 50% in patients with an
ANC of 500-1000 cells/mL and discontinued in those
with an ANC \500 cells/mL. Patients with GVHD
in CR at day 28 continued to receive MMF through
Biol Blood Marrow Transplant 16:421-429, 2010 423MMF Pharmacokinetics in Acute GVHDthe completion of the steroid taper, with MMF then
tapered over the subsequent 4 weeks.
aGVHD Response and Toxicity Assessment
aGVHD was clinically diagnosed or biopsy-
proven in all patients. GVHD was scored and overall
grade was assigned as defined by the Consensus Crite-
ria [35] at day 28, day 56, and then monthly for 9
months following the initiation of treatment. CR in
GVHD was defined as complete resolution of all signs
and symptoms of GVHD in all evaluable organs with-
out additional therapy. PR was defined as improve-
ment by at least one stage in one or more involved
organs without progression. A mixed response (MR)
was defined as improvement in at least one involved
organ with progression or newly developed GVHD
in one or more organs. No response (NR) was defined
as a lack of improvement or worsening in any organ
within 14 days of the start of therapy. Progression
was defined as worsening by one or more stages in
one or more organs without improvement in any
organ. Failure of therapy was defined as PR, MR,
NR, progression, death, or development of chronic
GVHD (cGVHD). Severe, fatal, or life-threatening
infections were recorded through day 90. Infections
were reported regardless of attribution to study treat-
ment and were graded according to the National Can-
cer Institute’s Common Terminology Criteria for
Adverse Events, version 3.0. Death from any cause
was considered an event in the survival analysis.
Mycophenolate Bioanalysis and
Pharmacokinetics
Total and unbound MPA and total MPAG in the
plasma were measured in each sample by high-perfor-
mance liquid chromatography (Series 1100 system;
Agilent Technologies, Wilmington, DE) with UV
detection as described previously [36,37]. The validated
assays were linear in the range of 0.025-20 mg/mL for
total MPA, 1-100 mg/mL for total MPAG, and 0.001-
0.5mg/mL forunboundMPA.Assay accuracy and intra-
day and interday variability (as percent relative standard
deviation) were 97%-111%, 0.6%-4.4%, and 1.0%-
6.0%, respectively, for total MPA; 97%-101%, 0.9%-
1.4%, and 0.7%-4.8% for MPAG; and 96%-118%,
0.7%-5.4%, and 0.5%-7.8% for unbound MPA.
Patients were evaluated at steady state with phar-
macokinetics in weeks 1 and 2 after initiation of
MMF treatment. Steady state was defined as .5 half-
lives from initiation ofMMF. A limited sampling strat-
egy was used, in which 4 blood samples were obtained
over 6 hours after MMF administration. Blood
samples (5 mL) were collected in purple-top tubes
containing EDTA at 0 (C0), 1 (C1), 2 (C2), and 6
(C6) hours after administration of an oral dose and at
0, 2, 4 (C4), and 6 hours after the start of i.v. infusion.Intravenous MMF was administered at a constant rate
over 2 hours. Blood samples were spun, and plasma
was removed and aliquoted into two 1.5-mL Eppen-
dorf screw cap vials, and then frozen at 220C. All
samples were shipped to a central laboratory at the
University of Minnesota for analysis. For each patient,
a total and unbound MPA area under the curve
(AUC)0-12 was determined from a limited sampling
model developed for HCT recipients [38]. For oral
administration, total AUC0-12, in mg hour/mL, was
4.43 1 2.76*C0 1 0.51*C1 1 1.97*C2 1 4.27*C6,
and unbound AUC0-12, in ng hr/mL, was 63.92 1
2.01*C0 1 0.67*C1 1 2.05*C2 1 4.26*C6. For i.v.
administration, total AUC0-12, in mg hour/mL, was
-0.491 1.58*C21 0.41*C41 13.88*C6, and unbound
AUC0-12, in ng hour/mL, was 7.99 1 1.40*C2 1
2.47*C4 1 9.54*C6. Total and unbound MPA
AUC0-6 and MPAG AUC0-6 were calculated by non-
compartmental analysis using WinNonLin version
5.2 (Pharsight Corp, Mountain View, CA). Steady-
state trough was the concentration at time 0 (C0).
Cmax was the highest observed concentration. The
free fraction of MPA was determined by calculating
the ratio of unbound MPA AUC0-6 to total MPA
AUC0-6. The MPAG:MPA ratio was determined
from the trough concentration.Statistical Analysis
The distribution of pharmacokinetic measures (to-
tal and unbound trough, AUC0-6 and AUC0-12, Cmax)
was evaluated. Week 1 and week 2 pharmacokinetic
measurements were compared using Wilcoxon’s
signed-rank test or McNemar’s test in patients with
both measurements. Comparisons of i.v. and oral
pharmacokinetics were conducted using Wilcoxon’s
rank-sum test or Fisher’s exact test. The association
among various pharmacokinetic measurements was as-
sessed using Spearman’s r. The association between
pharmacokinetic measurements (total and unbound
AUC0-6, AUC0-12 and troughs) and clinical outcomes
(CR, PR, CR1 PR, infection, survival) was conducted
by dichotomizing the outcome at select time points.
Pharmacokinetic measures were explored as continu-
ous variables using nonparametric tests to test the
association between outcomes and the MPA pharma-
cokinetic measurements. We postulated dichotomized
values using published data for each pharmacokinetic
measurement and performed chi-square tests or
Fisher’s exact tests to test the association between
dichotomized values and clinical endpoints. We ana-
lyzed the pharmacokinetic measurements at week 1
and week 2 separately, as well as the mean of weeks 1
and 2 to stabilize the measurement; the results were
generally consistent, so except as noted the mean of
weeks 1 and 2 data are presented. Although this is
an exploratory study, we considered adjustment for
Table 1. Patient Characteristics
Age, years, mean ± standard deviation 41 ± 13.6
Weight at time of study entry, kg,
mean ± standard deviation
82.6 ± 25.4
Primary disease, n (%)
Acute myelogenous leukemia 15 (46.9%)
Acute lymphoblastic leukemia 6 (18.8%)
Chronic myelogenous leukemia 2 (6.3%)
Myelodysplastic syndrome 1 (3.1%)
Lymphoma 4 (12.5%)
Other 4 (12.5%)
Donor source, n (%)
Related 16 (50%)
Unrelated 16 (50%)
Stem cell source, n (%)
Bone marrow 11 (34.3%)
Peripheral blood 19 (59.4%)
Cord blood 2 (6.3%)
GVHD prophylaxis at time of transplantation, n (%)
Tacrolimus/methotrexate 16 (50%)
Cyclosporine/other 6 (19%)
Cyclophosphamide 6 (19%)
Tacrolimus/other 4 (12%)
Calcineurin Inhibitor at time of pharmacokinetics
Tacrolimus 23 (72%)
Cyclosporine 3 (9%)
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measurements tested for association with GVHD
response, so that a p-value\ 0.05/6 5 0.0083 should
be considered significant after Bonferroni adjustment.
No further adjustment for the multiple PK time points
(week 1 vs. week 2 vs. average of weeks 1 and 2) or for
the multiple outcomes (day 28 CR1PR vs. day 56
CR1PR) were done because the tests were highly
correlated and consistent. We also examined the asso-
ciation between non-pharmacokinetic variables (con-
ditioning regimen, donor and graft source, GVHD
prophylaxis at transplantation and grade of GVHD
at enrollment) and outcome. Survival analysis was per-
formed to evaluate the association between pharmaco-
kinetic measures and overall survival. Dichotomized
results are reported since they provide interpretations
that can be used in clinical care. Multiple regression
analyses were not performed due to limited sample
size. SAS 9.1 statistical software was used for data
analysis.None 6 (19%)
Conditioning regimen, n (%)
Nonmyeloablative or reduced intensity 4 (12.5%)
Myeloablative 28 (87.5%)
Acute GVHD grade at time of enrollment, n (%)
I 1 (3.1%)
II 19 (59.4%)
III 12 (37.5%)
IV 0
GVHD indicates graft-versus-host disease.RESULTS
Pharmacokinetics
Mycophenolate pharmacokinetics were studied in
32 of the 45 patients randomized to MMF. Thirteen
of the patients were not studied because the patient
was unable or declined to undergo additional blood
sampling for pharmacokinetics, or was taken off
MMF therapy before sampling. Characteristics and
response to MMF treatment did not differ between
the 32 evaluable patients and the whole MMF group
(n=45, data not shown). Patient characteristics are
summarized in Table 1. Five patients were studied
only once, resulting in a total of 59 pharmacokinetic
profiles. Thirty patients receivedMMF 1 g twice daily,
and 2 patients received 0.75 g twice daily. MMF was
administered orally or i.v. based on clinical status.
Twenty patients received oral MMF during both
sampling periods. Median MPA pharmacokinetic
measures were similar in weeks 1 and 2 of treatment
except for total troughs, which were higher in week 2
(Table 2). Oral administration yielded 4- to 6-fold
higher trough concentrations than i.v. administration,
whereas i.v. administration provided higher AUC
values (Table 3). In all pharmacokinetic sets, the
median unbound MPA fraction was 2.2% (range,
0.9%-5.6%) and was significantly higher with i.v. ad-
ministration compared with oral administration. The
median MPAG:MPA ratio [range] was higher in
week 1 than in week 2 (66.0 [17.6-447.1] vs 45.7
[14.9-576.7]).
Total and unbound trough values were highly cor-
related in weeks 1 and 2 (Spearman’s r 5 0.88 and
0.87, respectively; P\ .001). Total trough and total
AUC0-12 were only moderately correlated in week 1(r 5 0.53; P 5 .003) and week 2 (r 5 0.75; P\ .001).
Correlations between unbound trough and unbound
AUC0-12 in weeks 1 and 2 were r 5 0.49 (P 5 .006)
and r 5 0.40 (P 5 .028), respectively.
GVHD Response and MPA Exposure
The majority of patients achieved either a CR (n5
21, 66%) or PR (n5 5, 15%) by day 28 after initiation
of therapy while the remaining 6 patients (19%) had ei-
ther NR or MR or GVHD progression. At day 56 the
response rates were 78% (n5 25) with CR, 6% (n5 2)
with PR, and 16% (n55) withNR,MR or progression.
Pharmacokinetic measurements (total and unbound
AUC0-6, AUC0-12, trough) at either 1 or 2 weeks did
not correlate with achieving CR at day 28 or 56
(p.0.07). However, higher mean trough concentra-
tions (taken by averaging the trough levels from both
weeks 1 and 2) were associated with a significantly
better combined CR1PR at both days 28 and 56.
As shown in Figure 1, patients whose mean total
trough of weeks 1 and 2 was .0.5 mcg/ml were
more likely to achieve CR1PR at day 28 than patients
with lower mean total troughs (19/19, 100% vs 7/13,
54%, p50.002). At day 56, a CR1PR was also higher
in those with a mean week 1 and 2 total trough
.0.5 mcg/mL than those with lower troughs (19/19,
100% vs 8/13, 62%, p = 0.006). These results were
Table 2. MPA Pharmacokinetics in Weeks 1 and 2 after Initiation of MMF Treatment*
Week 1 (n 5 29) Week 2 (n 5 30) P†
i.v./oral administration, n 11/18 7/23 .38‡
Day posttransplantation 36.0 (17-81) 46 (22-88)
Dose 1000 mg/750 mg, n 27/2 28/2
Serum creatinine, mg/dL 0.90 (0.4-1.7) 0.90 (0.4-2.8) .12
Total bilirubin, mg/dL 0.70 (0.2-19.7) 0.70 (0.3-21.7) .35
Serum albumin, g/dL 2.95 (1.6-4.3) 3.30 (1.5-3.9) .21
MPA, total
Trough, mg/mL 0.465 (0.036-2.54) 0.782 (0.0-5.10) .05
AUC0-6, mg*hour/mL 20.11 (5.86-44.1) 18.70 (3.8-53.7) .61
AUC0-12, mg*hour/mL 23.97 (7.9-44.4) 21.90 (11.6-76.2) .98
MPA, unbound
Trough, mg/mL 0.006 (0.0-0.106) 0.015 (0.0-0.149) .14
AUC0-6, mg*hour/mL 0.445 (0.093-0.126) 0.384 (0.099-2.80) .80
AUC0-12, mg*hour/mL 0.467 (0.169-1.33) 0.444 (0.176-3.257) .28
MPAG trough, mg/mL 32.88 (3.89-163.2) 33.76 (5.65-209.3) .27
MPA unbound fraction 0.0195 (0.012-0.044) 0.023 (0.009-0.056) .44
MMF indicates mycophenolate mofetil; MPA, mycophenolic acid; MPAG, mycophenolic acid glucuronide; PK, pharmacokinetics.
*Data are median (range); P is a comparison of week 1 and week 2 pharmacokinetics for only those subjects with an assessment at both week 1 and week
2 (paired analysis; n 5 27).
†Wilcoxon’s signed-rank test except where noted otherwise.
‡McNemar’s test (exact P value).
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for day 56) and week 2 (p = 0.003 for day 28, p =
0.003 for day 56) troughs separately. Not surprisingly,
higher mean unbound troughs also correlated with re-
sponse to treatment, although these were not signifi-
cant after adjustment for multiple comparisons. As
shown in Figure 2, patients with a mean of weeks 1
and 2 unbound troughs .0.015 mcg/ml were more
likely to achieve CR1PR at day 28 than patients
with lower mean unbound troughs (15/15, 100% vs
11/17, 65%, p 5 0.02). At day 56, a CR1PR was
also higher in those with a mean week 1 and 2 unbound
trough .0.015 mcg/mL than those with a lower
trough (15/15, 100% vs 12/17, 71%, p 5 0.04). The
mean of weeks 1 and 2 total and unbound AUC0-6
and AUC0-12 were not associated with a better com-
bined CR1PR at both days 28 and 56 (p $ 0.33,
data not shown).
Substantial numbers of patients had MPA expo-
sure below these determined trough thresholds. AtTable 3. Mycophenolate Pharmacokinetics During Intravenous and
Route of Administration i.v. (n
MMF dose, 1000 mg twice daily/750 mg twice daily, n 9
Day posttransplantation 35 (21
Total MPA
Trough (mg/mL) 0.22 (0.
AUC0-6, (mg*hour/mL) 20.36 (9.
AUC0-12, (mg *hour/mL) 21.12 (7.
Unbound MPA
Trough (mg/mL) 0.005 (0.
AUC0-6, (mg*hour/mL) 0.612 (0.
AUC0-12, (mg*hour/mL) 0.502 (0.
MPAG trough, mg/mL 39.29 (3.
MPA unbound fraction 0.029 (0.
MMF indicates mycophenolate mofetil; MPA, mycophenolic acid; MPAG, myco
*Data are median (range).
†P value is comparison of i.v. and oral pharmacokinetics by Wilcoxon’s rank-s
‡Fisher’s exact test.week 1, 16 of 29 patients (55%) had a total trough
\0.5 mg/mL, and 20 of 29 (69%) had an unbound
trough \0.015 mg/mL. At week 2, 11 of 30 (37%)
had a total trough\0.5 mg/mL, and 15 of 30 (50%)
had an unbound trough \0.015 mg/mL. Interest-
ingly, other variables, including donor type, graft
source, conditioning regimen, GVHD prophylaxis,
and GVHD grade at enrollment, were not associated
with response (all P . .09).Site of GVHD and MPA Exposure
GVHD organ involvement did not predict MPA
exposure, although the number of observations in our
study was limited. In patients with only skin GVHD
(n 5 10), the median MPA total and unbound trough
concentrations were 1.18 mg/mL (range, 0.02-2.11
mg/mL) and 0.017 mg/mL (0.002-0.032 mg/mL),
respectively. Patients with liver involvement (n 5 6)
had total and unbound trough concentrations ofOral Administration in Week 1 of Treatment*
5 11) Oral (n 5 18) P†
/2 18/0 .14‡
-81) 38.5 (17-74) .67
04-0.62) 0.96 (0.04-2.54) .0028
1-37.0) 18.76 (5.86-44.06) .57
9-32.57) 24.0 (11.4-44.41) .80
0-0.027) 0.014 (0-0.106) .03
262-1.262) 0.367 (0.093-1.15) .02
235-1.018) 0.450 (0.17-1.33) .20
89-89.99) 32.80 (4.6-163.23) .51
017-0.042) 0.017 (0.012-0.044) .005
phenolic acid glucuronide.
um test, unless noted otherwise.
Figure 1. Total MPA trough values by response at days 28 and 56 posttreatment. Troughs are the mean of weeks 1 and 2 in each subject. Only subjects
with both week 1 and 2 pharmacokinetics data are included. The box-and-whisker plots extend to the 5th and 95th percentiles.
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(0.004-0.021 mg/mL), respectively, whereas those with-
out liver involvement (n 5 26) had respective trough
concentrations of 0.81 mg/mL (0.021-2.88 mg/mL)
and 0.012 mg/mL (0-0.088 mg/mL). In patients with
lower GI involvement (n 5 13), total and unbound
MPA concentrations were somewhat lower, at 0.38
mg/mL (0.04-2.88 mg/mL) and 0.007 mg/mL (0.000-
0.088 mg/mL), respectively, whereas in those without
lower GI involvement (n 5 19), concentrations wereFigure 2. Unbound MPA trough values by response at days 28 and 56 posttr
subjects with both week 1 and 2 pharmacokinetics data are included. The boxgenerally higher, at 0.99 mg/mL (0.021-2.31 mg/mL)
and 0.015 mg/mL (0.0018-0.087 mg/mL).
Infections, OS, and MPA Exposure
Severe, life-threatening, or fatal infections (n5 12;
8 viral, 3 bacterial, and 1 fungal) occurred in 10 indi-
viduals by day 90 postrandomization. MPA exposure
measurements were not significantly different between
those with and without a serious infectious event (all
P . .19). There was no association between theeatment. Troughs are the mean of weeks 1 and 2 in each subject. Only
-and-whisker plots extend to the 5th and 95th percentiles.
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postrandomization (P $. 23).DISCUSSION
The pharmacokinetics and pharmacodynamics of
MMF have been studied extensively in solid organ
transplantation; however, relatively limited data are
available in HCT. Numerous studies have reported
a relationship between MMF pharmacokinetics and
development of acute allograft rejection in organ trans-
plantation, and, although controversial, most support
an association between higher MPA exposure and pro-
tection against acute rejection [33,39-42]. More recent
data in kidney transplantation indicate that prophylac-
tic calcineurin inhibitors can be safely minimized or
corticosteroidswithdrawn if totalMPA trough concen-
trations are maintained at .1.2 or 1.6 mg/mL, or if
AUC0-12 is$ 40 mg hour/mL [27,43]. To achieve these
targets, oralMMFdoses of 2.5-3 g/day are typically re-
quired [27]. Higher starting doses of MMF in kidney
transplantation are currently under investigation [33].
The optimal dose of MMF inHCT remains a mat-
ter of debate. Most centers have adopted the common
prophylactic dose for kidney transplantation of 1 g
twice daily. However, at this dose, plasma concentra-
tions are typically lower in HCT recipients relative to
organ transplant recipients, especially when combined
with cyclosporine (CsA) [18,22,23,28,34,44-52]. We
have previously studied mycophenolate pharmacoki-
netics early posttransplantation after nonmyeloablative
conditioning and found that low total MPA trough
concentrations are associated with poorer engraftment
and low unbound MPA AUCs are associated with
a higher rate of acute GVHD [23]. Similarly, Giaccone
et al. [28] reported an association between low total
MPA exposure and lower donor T cell chimerism after
nonmyeloablative HCT. A dose of 3 g/day is typically
required to achieve the target concentrations defined
in those studies when combined with CsA [37].
The use of MMF to treat aGVHD is increasing,
and data from BMT CTN trial 0302 suggest that
MMFplus corticosteroidsmay have significant activity
against GVHD [16]. In the treatment setting, MPA
pharmacokinetic disposition, exposure–response rela-
tionship, and optimal dosing are unclear. Two earlier
studies evaluating the use of MMF to treat aGVHD
and cGVHD suggested a better GVHD response in
patients with higher MPA exposure; both studies
were small, however [34,53]. In the current pharmaco-
kinetic analysis conducted with BMT CTN 0302, we
found that patients with a total MPA trough concen-
tration .0.5 mg/mL or an unbound trough .0.015
mg/mL were more likely to achieve CR 1 PR at day
28 and day 56. MPA exposure was below these
therapeutically favorable thresholds in 55%-69% ofsubjects in week 1 of MMF treatment and in 37%-
50% of subjects in week 2. These data suggest that
an MMF dose of .2 g/day may be required in a sub-
stantial number of patients.
Higher doses of MMF (3 g/day) are increasingly
common in the prophylactic setting. Significantly
higher donor T cell chimerismwas observed in a group
of patients receiving prophylactic MMF 3 g/day com-
pared with those receiving 2 g/day [54]. Although
there was a slightly higher rate of infection in the
3-g/day group, no difference in OS or progression-
free survival (PFS) was observed. Studies in kidney
transplantation and HCT have shown a higher
incidence of leukopenia or cytomegalovirus (CMV)
reactivation in patients with high MPA exposure
[28,30,31,55]. In our analysis, only a small number of
patients achieved exposure levels potentially associated
with these events. Although higher MMF doses might
result in more patients’ MPA exposure in the range as-
sociated with higher risk of infectious complications,
no data in the context of GVHD treatment supports
this conjecture. The risk may be mitigated by better
GVHD control and more rapid discontinuation of im-
munosuppression. In the current study, we found no
association between higher MPA exposure and in-
creased rate of infection.
Several factors that affect MMF pharmacokinetics
warrant discussion. First, the potential effect of intes-
tinal and liver GVHD on MPA disposition is of con-
cern. MPA is metabolized in the intestine and liver,
common sites of GVHD involvement. A pilot study
of 14 patients treated with MMF for aGVHD found
lower total MPA concentrations in patients with intes-
tinal GVHD compared with those with skin or liver in-
volvement [34]. This finding is supported by our
analysis, which revealed lower trough concentrations
in patients with lower GI or liver GVHD compared
with those with skin- only involvement. Larger studies
with pharmacokinetic analyses are needed to deter-
mine whether the site of GVHD involvement affects
dosing recommendations. Second, steroids are potent
inducers of glucuronidation of many substrates in vitro
and might affect MPAmetabolism, which is highly de-
pendent on glucuronidation to form its metabolites,
including the major metabolite, MPAG [56]. MPAG
is known to displace MPA from protein-binding sites,
thereby increasing unbound MPA. It is possible that
steroids may induce glucuronidation, thereby enhanc-
ing MPAG formation and lowering MPA concentra-
tions. The effect of corticosteroids on MPA
metabolism has been studied in organ transplantation,
with conflicting conclusions [57,58]. In our analysis,
theMPAG:MPA exposure ratio was high (45-66) com-
pared with the ratios of around 30 reported in other
HCT studies [23,59]. This suggests that MPAG for-
mation may be enhanced or MPAG excretion may be
reduced. MPAG readily accumulates in renal
428 Biol Blood Marrow Transplant 16:421-429, 2010P. A. Jacobson et al.dysfunction; however, the mean serum creatinine in
our subjects was 0.9 mg/dL; therefore it is unlikely
thatMPAG accumulated as a result of poor renal clear-
ance alone. Therefore, high dose corticosteroids may
affect the formation of MPAG and MPA concentra-
tions; however, this requires confirmation in formal
drug interaction studies. Finally, MPA concentrations
are lower in patients receiving CsA compared to tacro-
limus; therefore; MMF dose requirements may vary
depending on the underlying calcineurin inhibitor
[60,61]. Although the MPA exposure target is likely
the same for either regimen.
Interestingly, total MPA trough concentrations
were higher in subjects receiving oral MMF than in
those receiving i.v. MMF. We have seen this in our
other MMF pharmacokinetic studies as well, and sus-
pect that it may be secondary to enterohepatic recircu-
lation ofMPAG or delayed absorption of the oral solid
formulations. MPA metabolites, particularly MPAG,
are available in the gut and are subject to deglucuroni-
dation back to MPA, which is then reabsorbed into the
systemic circulation. Although CsA is known to block
enterohepatic recirculation of MPA, some recircula-
tion may still occur (albeit to a limited extent), result-
ing in slightly higherMPA trough concentrations after
oral administration.
In conclusion, MPA total trough concentrations
.0.5 mcg/mL or unbound concentrations .0.015
mcg/mL may be associated with better aGVHD re-
sponse at day 28 and 56 post treatment. There was
no association betweenMPA pharmacokinetics and in-
fections or survival.MMF1 gm every 12 hours achieves
these threshold concentrations in approximately 50%
of patients and higher doses may be required in many
patients to achieve these therapeutically effective
targets. These data should be confirmed in future inde-
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